COMP (rat):Angiopoietin-1 (human) (rec.)

The complex multi-domain structure of native human Angiopoietin-1 has hindered its widespread applicability, prompting the search for alternative approaches to mimicking the Ang1:Tie2 signalling axis; a system with highly complex patterns of regulation. The engineered variant, Cartilage Oligomeric Matrix Protein-Angiopoietin-1 (COMP-Ang1), has been demonstrated to overcome the limitations of the native molecule and activate the Tie2 pathway with several-fold greater potency than Ang1, both in vitro and in vivo. COMP-Ang1 is a soluble, stable and more potent angiopoietin-1 (Ang-1) variant. The therapeutic efficacy of COMP-Ang1, at both the vascular and systemic levels, is evident from multiple studies. Beneficial impacts on skeletal muscle regeneration, wound healing and angiogenesis have been reported alongside renoprotective, anti-hypertensive and anti-inflammatory effects. COMP-Ang1 has also demonstrated synergy with other compounds to heighten bone repair and has received considerable attention as an anti-leakage agent for microvascular diseases like diabetic retinopathy.